SUZHOU, China, April 14, 2021 /PRNewswire/ -- Kintor
Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical"
or the "Company"), a clinical-stage biotechnology company
developing innovative small molecule and biological
therapeutics, recently announced a strategic partnership with
Hainan Visum Pharmaceutical Limited ("Visum") to expand
proxalutamide manufacturing.
At present, Kintor Pharmaceutical is completing the
Brazilian clinical trials of proxalutamide for treatment of
male and female COVID-19 patients with mild or moderate symptoms
and COVID-19 patients with severe symptoms. Preliminary data
indicates that after proxalutamide treatment, the risk of
hospitalization for male patients with mild or moderate COVID-19
symptoms is reduced by 100%, while that of female patients is
reduced by 90%. The risk of death for patients with severe symptoms
is reduced by 92%, and the hospital stay is shortened by 9
days.
Kintor Pharmaceutical recently announced that its
Investigational New Drug (IND) application for Phase III clinical
of proxalutamide for the treatment of COVID-19 patients has been
approved by the United States Food and Drug Administration.
Dr. Youzhi Tong, co-founder,
chairman, and CEO of Kintor Pharmaceutical, said, "We are pleased
to partner with Visum. With the clinical progress Kintor is making
with proxalutamide for COVID-19 indications, Kintor needs to
rapidly expand its existing GMP production capacity to cope with
the demand necessary to fight the epidemic. Visum has demonstrated
technical strength in research and development, and the production
of pharmaceutical products with stringent quality standards and
extensive experience with U.S. FDA certifications. We believe that
our partnership with Visum will offer proxalutamide as a
significant contribution to the global COVID-19 prevention and
control efforts."
Dr. Zhu Honggang, chairman of Visum, said, "It is a great honor
to be able to provide high-quality and high-efficiency
manufacturing services for Kintor as they approach regulatory
approvals for proxalutamide. Since our founding in 2010, Visum has
consistently adhered to the highest international quality standards
and passed on-site inspections by the U.S. FDA with "zero defect."
Visum looks forward to making full use of our existing high-end
preparation processing production lines, and the high-standard and
high-specification quality control systems to accelerate the
availability of proxalutamide in the fight against Covid 19."
About Kintor Pharmaceutical Limited
Kintor Pharmaceuticals is developing and commercializing a
robust pipeline of innovative small molecule and biological
therapeutics for androgen-receptor-related disease areas with unmet
medical needs, including COVID-19, prostate, breast and liver
cancer, alopecia and acne. For more information, visit
www.kintor.com.cn.
About Visum
Located in Haikou national
high-tech development zone, Hainan Visum Pharmaceutical Limited was
founded in June 2010 by a team of
physicians who studied pharmaceutical research and development in
the United States. Visum is a
comprehensive international pharmaceutical enterprise that focuses
on new drug research and development and integrates production and
sales. Visum is the first R&D, production and export base of
high-end oral solid preparation in Hainan. The technical team of the Company
consists of high-tech talent from world-renowned pharmaceutical
enterprises and experienced domestic pharmaceutical talents, with
experience in the development and industrialization of over 100
varieties of products, familiar with the technologies of
development of sustained-release and controlled release
preparations, insoluble pharmaceutical products, pharmaceutical
products with complicated production process and unstable products,
including technologies of pellet coating, matrix tablets, solid
dispersion tablets, multi-layer tablets, small pellet tablet and
others. Visum's self-developed metoprolol succinate
sustained-release tablets and paroxetine hydrochloride
enteric-coated sustained-release tablets have already been launched
in the United States. With its
world-class R&D capability, sound manufacturing process, strict
quality system and high-quality services, Visum has become the CDMO
partner of numerous enterprises in China and abroad. Welcome to visit the
company's website: www.visumpharma.com.
View original
content:http://www.prnewswire.com/news-releases/kintor-pharmaceutical-and-visum-announced-strategic-partnership-to-expand-proxalutamide-manufacturing-301268908.html
SOURCE Kintor Pharmaceuticals